Polyvalent envelope glycoprotein vaccine elicits a broader neutralizing antibody response but is unable to provide sterilizing protection against heterologous Simian/human immunodeficiency virus infection in pigtailed macaques.
about
The aftermath of the Merck's HIV vaccine trialAlphavirus-adjuvanted norovirus-like particle vaccines: heterologous, humoral, and mucosal immune responses protect against murine norovirus challengeHIV-1 neutralizing antibodies: understanding nature's pathwaysAiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidatesPreclinical and clinical development of a multi-envelope, DNA-virus-protein (D-V-P) HIV-1 vaccineHIV envelope gp120 activates LFA-1 on CD4 T-lymphocytes and increases cell susceptibility to LFA-1-targeting leukotoxin (LtxA)Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodiesInfectious simian/human immunodeficiency virus with human immunodeficiency virus type 1 subtype C from an African isolate: rhesus macaque model.Human immunodeficiency virus type 1 envelope gp120 induces a stop signal and virological synapse formation in noninfected CD4+ T cells.Human immunodeficiency virus type 1 envelope gp120-induced partial T-cell receptor signaling creates an F-actin-depleted zone in the virological synapseImmunogenicity of a polyvalent HIV-1 candidate vaccine based on fourteen wild type gp120 proteins in golden hamstersNeutralizing antibody titers conferring protection to macaques from a simian/human immunodeficiency virus challenge using the TZM-bl assay.Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys.Similar T-cell immune responses induced by group M consensus env immunogens with wild-type or minimum consensus variable regions.Immunogen sequence: the fourth tier of AIDS vaccine design.Transfer of neutralizing IgG to macaques 6 h but not 24 h after SHIV infection confers sterilizing protection: implications for HIV-1 vaccine development.Control of viremia and prevention of simian-human immunodeficiency virus-induced disease in rhesus macaques immunized with recombinant vaccinia viruses plus inactivated simian immunodeficiency virus and human immunodeficiency virus type 1 particlesComparison of neutralizing antibody responses elicited from highly diverse polyvalent heterotrimeric HIV-1 gp140 cocktail immunogens versus a monovalent counterpart in rhesus macaquesCross-subtype T-cell immune responses induced by a human immunodeficiency virus type 1 group m consensus env immunogenDetermination of a statistically valid neutralization titer in plasma that confers protection against simian-human immunodeficiency virus challenge following passive transfer of high-titered neutralizing antibodiesEffect of the V3 loop deletion of envelope glycoprotein on cellular responses and protection against challenge with recombinant vaccinia virus expressing gp160 of primary human immunodeficiency virus type 1 isolates.A multivalent clade C HIV-1 Env trimer cocktail elicits a higher magnitude of neutralizing antibodies than any individual component.Improved protection of rhesus macaques against intrarectal simian immunodeficiency virus SIV(mac251) challenge by a replication-competent Ad5hr-SIVenv/rev and Ad5hr-SIVgag recombinant priming/gp120 boosting regimen.Engineering, expression, purification, and characterization of stable clade A/B recombinant soluble heterotrimeric gp140 proteins.Efficient protein boosting after plasmid DNA or recombinant adenovirus immunization with HIV-1 vaccine constructsOptimization of HIV-1 Envelope DNA Vaccine Candidates within Three Different Animal Models, Guinea Pigs, Rabbits and Cynomolgus MacaquesThe roles of nonhuman primates in the preclinical evaluation of candidate AIDS vaccines.Requirement of diverse T-helper responses elicited by HIV vaccines: induction of highly targeted humoral and CTL responses.Centralized immunogens as a vaccine strategy to overcome HIV-1 diversity.Standardized assessment of NAb responses elicited in rhesus monkeys immunized with single- or multi-clade HIV-1 envelope immunogensEvaluation of heterologous vaginal SHIV SF162p4 infection following vaccination with a polyvalent Clade B virus-like particle vaccineAiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates.A Simple Mouse Model for the Study of Human Immunodeficiency Virus.Problems and emerging approaches in HIV/AIDS vaccine development.Polyvalent AIDS vaccines.Viral sequence diversity: challenges for AIDS vaccine designs.Immunogenicity of constrained monoclonal antibody A32-human immunodeficiency virus (HIV) Env gp120 complexes compared to that of recombinant HIV type 1 gp120 envelope glycoproteins.Induction of disease by a molecularly cloned highly pathogenic simian immunodeficiency virus/human immunodeficiency virus chimera is multigenic.Analysis of pigtail macaque major histocompatibility complex class I molecules presenting immunodominant simian immunodeficiency virus epitopes.Universal vaccines: shifting to one for many or shooting too high too soon!
P2860
Q24654458-D1169F83-6CCF-4FDA-9B98-83C62298BCE1Q24657762-2F154115-5056-4A34-92C2-CBDDC613A840Q27000480-1FFBBBC1-8B74-4052-BC95-457FE1727955Q27489000-39E6A399-FB9B-4C06-A5B2-8F80B23D2725Q28387636-A230A962-6750-4EB8-9D85-64F9B6FAA8C0Q28741718-E5AAEBD7-9669-47A4-B49C-1850515B04E3Q29619015-947F27F1-F25F-4C6D-AE0D-D028F168248AQ30329167-47BECA8A-2A9D-442C-A2F5-1091B898F545Q30483680-19FE04AD-73EA-471C-8B06-2F2D46974813Q30491420-1F406A2E-E0C0-443D-B3AD-B9F2716F645DQ33262275-47981ECB-59F9-406A-A779-B249F32AF634Q33807535-6F595387-E147-437C-A62B-44688E6C4A03Q33984182-A2473244-9073-4372-AF16-8BB66BBDF6ADQ34103170-D1481086-389F-4DE4-958F-5033108C21E8Q34337482-503BE3D3-3B9B-4DDC-8ACA-ED263C8BDC05Q34391256-7ECC4565-0E4D-41F7-99B0-E1FD3D129917Q34465510-FDC68ED6-1C89-4640-8254-9E66E2ABD592Q34663118-E9B3ABA2-61C2-4A38-95F0-71D694066B66Q34717906-C7E2EDC4-BF2E-4D3F-84E6-EE669164BA31Q34970873-086AEACE-37A0-4F92-ACB1-01B5E7C3CE54Q34999946-1A9C4661-1901-4EF9-9938-C00A456B34F7Q35076748-CC6EA420-562F-4371-AF32-9F3662BA6CF8Q35155380-5180CA81-9165-4BE7-A0E1-537F9F5B10ACQ35666057-A6691AB2-B5AD-49CB-BBD7-038B193ABF56Q35677724-105C5ED2-48B1-4E07-9371-4F45181B5F35Q35826692-401E6848-B216-4885-B8A0-7D4E4C24F349Q35851774-9657C4FC-53FF-491E-9449-3D71FBDB8D2FQ35851778-BFE4AA4A-143B-4F8D-AD77-EB899F383958Q35851815-0EFF3053-2D5D-4B04-B240-F9CB717B1FA7Q36138144-769071D1-A2DD-4E5D-BA71-BFB80BBCED7AQ36177537-08CC4A09-6375-4A66-9F10-21453171FFC2Q36600380-C393E310-3174-4375-8430-678D8BF22B62Q36601933-7C6C5896-425B-4699-A5C5-935599B1CF52Q36758574-961B54E6-B2B5-41A7-AED4-39FBDE84AFBCQ37094429-C755DB38-20ED-4125-BDD1-828384F24A61Q37316023-05AE16EA-8D6F-4F8E-A1F8-F75A3171CAF9Q37730028-FF1DCA83-C41D-4F2B-BD64-28530E107A76Q37730045-5BB5A5E6-96EF-4AC5-B9B0-AB93C9A66F59Q37743044-C9A01453-9C00-4FB2-89EA-80662912EF70Q37919551-A6B59931-0258-4A02-A2E9-165F1AE70A86
P2860
Polyvalent envelope glycoprotein vaccine elicits a broader neutralizing antibody response but is unable to provide sterilizing protection against heterologous Simian/human immunodeficiency virus infection in pigtailed macaques.
description
2001 nî lūn-bûn
@nan
2001 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մարտին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Polyvalent envelope glycoprote ...... fection in pigtailed macaques.
@ast
Polyvalent envelope glycoprote ...... fection in pigtailed macaques.
@en
type
label
Polyvalent envelope glycoprote ...... fection in pigtailed macaques.
@ast
Polyvalent envelope glycoprote ...... fection in pigtailed macaques.
@en
prefLabel
Polyvalent envelope glycoprote ...... fection in pigtailed macaques.
@ast
Polyvalent envelope glycoprote ...... fection in pigtailed macaques.
@en
P2093
P2860
P1433
P1476
Polyvalent envelope glycoprote ...... fection in pigtailed macaques.
@en
P2093
A Buckler-White
D C Montefiori
M A Martin
T Igarashi
P2860
P304
P356
10.1128/JVI.75.5.2224-2234.2001
P577
2001-03-01T00:00:00Z